Hemab Therapeutics Holdings, Inc.(COAG)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Not in ranked universe
Below size threshold
Quality rankings require at least $50M annual revenue or $250M total assets to filter out micro-caps and shell companies. This company reported $0.0M in revenue.
Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.
COAG Stock Analysis & AI Quality Score
AI stock analysis and institutional research for Hemab Therapeutics Holdings, Inc. (COAG), a Healthcare sector company. COAG is not currently included in 13F Pro's AI-ranked quality universe — quality rankings require at least $50m annual revenue or $250m total assets to filter out micro-caps and shell companies. this company reported $0.0m in revenue. Based on the latest XBRL financial filings (Q1 2026), Hemab Therapeutics Holdings, Inc. reports net income of $-22.7M, free cash flow of $-21.7M. COAG trades on the Nasdaq exchange and files with the SEC under CIK 2114044. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate COAG daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Hemab Therapeutics Holdings, Inc. directly from SEC EDGAR.
Net Income
Q1 2026
$-22.7M
Free Cash Flow
Q1 2026
$-21.7M
AI Insight: COAG Financial Trends
Hemab is burning cash with no revenue and negative equity, signaling severe financial distress.
• Operating loss of $24M and operating cash outflow of $22M in Q1 2026 with zero revenue.
• Equity position deteriorated to negative $199M, indicating liabilities exceed assets.
⚠ Net loss of $23M with no offsetting revenue—runway and path to profitability critical unknowns.
AI Insight: COAG Ratio Trends
Hemab is pre-revenue or early-stage with severely negative profitability; insufficient data to assess operational trends.
• Q1 2026 shows ROA of -51.8%, indicating substantial operating losses relative to total assets.
⚠ Single quarter of data; no historical trend visible. Path to profitability and cash burn rate are critical unknowns.
Get alerted when COAG's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for Hemab Therapeutics Holdings, Inc. including:
More Healthcare Companies
View all Healthcare →Put COAG on your watchlist
Track score changes the day Hemab Therapeutics Holdings, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is COAG a good stock to buy?
13F Pro's AI-powered analysis of Hemab Therapeutics Holdings, Inc. (COAG) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for COAG are available on the COAG stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.
Which hedge funds own COAG?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling COAG. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Hemab Therapeutics Holdings, Inc.'s investment landscape.